Where AI meets biology — the breakthroughs changing diagnosis, treatment, and prevention. Daily coverage of AI drug discovery, digital therapeutics, FDA milestones, and the startups building the future of healthcare.
Blog / RSS8 sources · 50 posts
Paul Markovich’s 4 Ideas to Reduce Healthcare Costs - MedCity News
medcitynews.com·Jun 15, 2026
Healthcare costs in the U.S. are rising unsustainably, prompting Paul Markovich, CEO of Ascendiun, to advocate for systemic reforms through a new policy movement called Worthy. Key proposals include implementing digital health records, shifting to outcome-based payment models, making prescription drugs more affordable, and placing healthcare organizations on a budget to control costs.
Paul Markovich's proposal to implement comprehensive, real-time digital health records for every American stands out as a transformative opportunity for the healthtech sector. This initiative, which a...
Rocket Pharma Reaps $180M From Sale of FDA Drug Review Fast Pass - MedCity News
medcitynews.com·Jun 14, 2026
Rocket Pharmaceuticals sold its rare disease pediatric priority review voucher for $180 million to support its pipeline, which includes a gene therapy for Danon disease, a condition with no FDA-approved treatments. The sale reflects increasing demand for such vouchers, with prices rising from around $100 million in previous years.
The sale of Rocket Pharmaceuticals' rare disease pediatric priority review voucher for $180 million underscores the increasing value of these regulatory fast passes, with prices rising from around $10...
Get this feed in your inbox
Free digest emails with the latest posts — no account needed.
Eli Lilly invests in startup Abridge for clinical trial recruitment
endpts.com·Jun 12, 2026
Eli Lilly has invested in health tech startup Abridge as it aims to enhance clinical trial recruitment and expand its presence in the life sciences sector.
Eli Lilly's investment in Abridge, a health tech startup expanding into clinical trial recruitment, signifies a strategic move toward leveraging digital platforms to streamline and potentially increas...
STAT+: Up and down the ladder: The latest comings and goings
statnews.com·Jun 12, 2026
The article highlights recent job changes in the pharmaceutical industry, including the hiring of Michelle Mellion as chief medical officer at AstronauTx, previously held roles at PepGen and EveryONE Medicines. It invites readers to share news about personnel changes in the sector.
The content provides no relevant insights or actionable takeaways specific to your interests in healthtech, biotech, digital health, or AI drug discovery. It primarily reports on personnel changes wit...
Enliven prices $400M offering; Jazz drug Zepzelca fails confirmatory study
endpts.com·Jun 12, 2026
Enliven Therapeutics has priced a $400 million offering, while Jazz Pharmaceuticals' drug Zepzelca has failed a confirmatory study.
The most valuable insight for a professional in healthtech and biotech from this content is that Enliven Therapeutics has priced a $400 million offering, a significant capital raise that could signal ...
STAT+: Prometheus raises $12 billion in capital for artificial engineers
statnews.com·Jun 12, 2026
Prometheus has successfully raised $12 billion to develop "artificial general engineers" in biopharma, while Abridge has formed partnerships with Eli Lilly and Nvidia to improve clinical trial recruitment. Additionally, a nonprofit organization has acquired a cancer drug for pediatric leukemia, intending to distribute it for free.
Prometheus' substantial $12 billion capital raise for developing "artificial general engineers" highlights the significant investment and interest in AI's potential to transform biopharma, particularl...
Sciwind has two Western partners for its obesity drug, but is open to more
endpts.com·Jun 12, 2026
Sciwind Biosciences has partnered with Pfizer and Verdiva Bio to license its obesity drug, ecnoglutide, but is seeking additional partnerships to expand its reach.
The key insight for you is that Sciwind Biosciences, despite already having licensed its GLP-1 obesity drug to Pfizer and Verdina Bio, is actively seeking additional Western partners. This indicates p...
Summit Therapeutics has withdrawn its plans for a $500 million offering, citing unfavorable market conditions, despite the biotech sector recently achieving a record IPO.
For a professional in the healthtech and biotech sectors, the key takeaway from this content is the volatility in the biotech financing environment. Summit Therapeutics' decision to withdraw a $500 mi...
Sensorion axes hearing loss program; Novartis' biomarker data in muscular dystrophy
endpts.com·Jun 11, 2026
Sensorion has discontinued one of its hearing loss programs while selecting another as its lead gene therapy candidate. Additionally, Novartis has released biomarker data related to muscular dystrophy.
The most valuable insight for you in this content is the decision by Sensorion to discontinue one of their hearing loss programs, which can signal shifts in strategic focus within the biotech sector. ...
STAT+: Novartis doubles down on molecular glue strategy
statnews.com·Jun 11, 2026
Novartis is intensifying its focus on molecular glue therapies, while also addressing rising drug costs for seniors and showcasing promising early data from Enliven's leukemia drug. Additionally, SonoThera has secured $125 million to further its ultrasound-based gene delivery approach.
Novartis's decision to expand its molecular glue strategy is a significant development in drug discovery, potentially offering new therapeutic avenues and investment opportunities. This strategic move...
<a href="https://www.fiercebiotech.com/biotech/genentech-executes-another-round-layoffs-3-vps-axed" hreflang="en">Genentech executes another round of layoffs, with 3 VPs axed</a>
fiercebiotech.com·Jun 11, 2026
Genentech has announced layoffs affecting several vice presidents as part of a restructuring within its Research and Early Development group, aimed at aligning resources with core therapeutic areas. This follows previous job cuts and reflects the company's ongoing adjustments to maintain competitiveness in the biotech industry.
Genentech's recent layoffs, including high-level VPs, signify a strategic shift in their research focus, particularly the closure of physiological chemistry and infectious disease units. For someone t...
What Healthcare Leaders Get Wrong About EHR Switching - MedCity News
medcitynews.com·Jun 11, 2026
Physicians express significant dissatisfaction with electronic health records (EHRs), which often stem from administrative burdens and hidden costs that complicate transitions between systems. Successful EHR migrations require careful planning, including clear contract terms and an emphasis on user engagement, to ensure that the chosen system supports evolving healthcare needs rather than hindering them.
For someone interested in healthtech and digital health, the key insight is that when selecting or switching EHR systems, healthcare organizations should prioritize platforms that support AI-driven wo...
<a href="https://www.fiercebiotech.com/pharma/novo-reports-cybersecurity-breach-tells-clinical-trial-patients-remain-vigilant" hreflang="en">Novo reports data breach, tells clinical trial patients to 'remain vigilant'</a>
fiercebiotech.com·Jun 11, 2026
Novo Nordisk has reported a data breach affecting some internal IT systems, which exposed de-identified patient information from its clinical trials. The company advises patients to remain vigilant but emphasizes that their core business remains unaffected.
The increase in cybersecurity threats targeting biopharma companies, as evidenced by Novo Nordisk's recent data breach affecting clinical trial patient data, underscores the critical need for robust c...
STAT+: ‘Synthetic lethality’ could trigger another round of biotech M&A
statnews.com·Jun 11, 2026
The promising results from early-stage clinical trials involving "synthetic lethality" in cancer treatment may lead to increased mergers and acquisitions in the biotech sector, particularly between companies like Revolution Medicines and Tango Therapeutics, as they explore innovative drug combinations for pancreatic cancer.
The concept of "synthetic lethality" in cancer treatment is gaining traction and could be a catalyst for significant mergers and acquisitions in the biotech sector. Specifically, the promising results...
Neion Bio raises $23M Series A to make proteins from chicken eggs
endpts.com·Jun 11, 2026
Neion Bio has raised $23 million in an oversubscribed Series A funding round to advance its technology that utilizes chicken eggs for producing active pharmaceutical ingredients.
Neion Bio's successful $23 million Series A funding round to develop technology for producing active pharmaceutical ingredients from chicken eggs highlights a significant investment opportunity in bio...
<a href="https://www.fiercebiotech.com/medtech/roche-garners-eu-approval-label-expansions-companion-dx-platform" hreflang="en">Roche nabs EU approval on label expansions for companion dx platform</a>
fiercebiotech.com·Jun 11, 2026
Roche has received EU approval for label expansions of its Ventana MMR RxDx companion diagnostic platform, which assesses cancer patients' mismatch repair status, enhancing treatment decision-making for various solid tumors. Meanwhile, the company is maintaining its €600 million investment in a new diagnostic production site in Germany, despite other pharmaceutical companies reducing their investments in the region.
Roche's recent EU approval for label expansions on its companion diagnostic platform, Ventana MMR RxDx, highlights a significant strategic advancement in precision medicine, particularly for cancer tr...
<a href="https://www.fiercebiotech.com/medtech/predicta-links-spanish-university-offer-diagnostic-blood-cancers" hreflang="en">Predicta links with Spanish university to offer diagnostic for blood cancers</a>
fiercebiotech.com·Jun 11, 2026
Predicta Biosciences has partnered with the Clínica Universidad de Navarra’s CIMA Lab Diagnostics to launch a new assay for diagnosing blood cancers, combining Predicta's GenoPredicta assay with advanced flow cytometry technology. This collaboration aims to enhance the detection and monitoring of blood cancers in Spain and other EU countries.
Predicta Biosciences' collaboration with the Clínica Universidad de Navarra’s CIMA Lab Diagnostics to develop the GenoPredicta assay for blood cancers is a significant step in precision oncology, leve...
<a href="https://www.fiercebiotech.com/biotech/cardiovascular-focused-kardigan-plans-bring-cozy-320m-haul-upcoming-ipo" hreflang="en">Cardiovascular-focused Kardigan plans to bring in cozy $320M haul from upcoming IPO</a>
fiercebiotech.com·Jun 11, 2026
Kardigan, a Bay Area biotech focused on cardiovascular treatments, is set to raise $320 million through its upcoming IPO on Nasdaq, offering 23.3 million shares priced between $14 and $16 each. The funds will primarily support the development of its lead drug, danicamtiv, and other assets targeting various heart conditions.
Kardigan's upcoming IPO, aiming to raise $320 million, highlights a strategic focus on advancing its innovative cardiovascular pipeline with assets like danicamtiv and ataciguat. For a professional tr...
<a href="https://www.fiercebiotech.com/biotech/caribou-boosts-case-shelf-car-t-matches-autologous-drugs-ahead-phase-3" hreflang="en">Caribou boosts case that off-the-shelf CAR-T matches autologous drugs ahead of phase 3</a>
fiercebiotech.com·Jun 11, 2026
Caribou Biosciences has reported that its allogeneic CAR-T therapy, vispacabtagene regedleucel (vispa-cel), achieved a median progression-free survival of 17.1 months in lymphoma patients, outperforming existing autologous therapies like Breyanzi and Yescarta. Despite the promising results, the company faces challenges in securing investor support and funding for its upcoming phase 3 trial targeting patients who are ineligible for traditional autologous treatments.
Caribou Biosciences' allogeneic CAR-T cell therapy candidate, vispa-cel, has shown promising median progression-free survival (PFS) of 17.1 months, surpassing the PFS of approved autologous therapies ...
<a href="https://www.fiercebiotech.com/biotech/fierce-biotech-heading-uk-host-event-amid-london-life-sciences-week" hreflang="en">Fierce Biotech heading to UK to host event amid London Life Sciences Week</a>
fiercebiotech.com·Jun 11, 2026
Fierce Biotech will host a one-day event in London on November 17, 2026, during London Life Sciences Week, focusing on scientific innovation, drug development, and investment trends in the biotech sector. The event aims to connect leaders from biotech, pharma, and investment to discuss key industry conversations.
For a professional interested in healthtech and biotech, the upcoming Fierce Biotech event in London during the Life Sciences Week on November 17th offers a valuable networking opportunity to connect ...
Takeda's TYK2 inhibitor, zasocitinib, has outperformed Bristol Myers Squibb’s Sotyktu in a phase 3 trial for treating moderate-to-severe plaque psoriasis, achieving over 35% complete skin clearance compared to Sotyktu's 14%. This success positions Takeda favorably ahead of its planned launch of zasocitinib in early 2027.
Takeda's successful phase 3 trial results for its TYK2 inhibitor zasocitinib, which showed significant superiority over Bristol Myers Squibb's Sotyktu in treating moderate-to-severe plaque psoriasis, ...
<a href="https://www.fiercehealthcare.com/payers/ahip-2026-why-ascendiun-ceo-paul-markovich-bullish-building-out-digital-health-record" hreflang="en">AHIP 2026: Why Ascendiun CEO Paul Markovich is bullish on building out a digital health record for patients</a>
fiercehealthcare.com·Jun 10, 2026
At AHIP 2026, Ascendiun CEO Paul Markovich emphasized the need for a comprehensive digital health record for every patient, arguing that mere interoperability is insufficient for improving patient care. He highlighted Blue Shield of California's efforts to enhance digital health records and called for broader industry support and policy reform to advance this initiative.
The key insight for you is the strategic shift from focusing on interoperability to establishing comprehensive digital health records for all patients, as emphasized by Paul Markovich, CEO of Ascendiu...
Rare disease biotech Beren adds $300M from new financings
endpts.com·Jun 10, 2026
Beren Therapeutics has secured $300 million in new financing as it awaits an FDA decision this fall for its rare disease drug, positioning itself for a potential launch.
Beren Therapeutics has secured $300 million in new financing to prepare for the potential FDA approval of its rare disease drug this fall. This significant capital injection signals confidence from in...
Parabilis Medicines’ Quest to Drug the Undruggable Picks Up $745M From Upsized IPO - MedCity News
medcitynews.com·Jun 10, 2026
Parabilis Medicines has developed a novel therapeutic approach targeting "undruggable" proteins, focusing on cancer, and has raised $745 million through its IPO, with its lead drug candidate, zolucatetide, showing promise in treating desmoid tumors. The company's Helicon peptides are designed to penetrate cells and engage difficult protein targets, combining the benefits of small molecules and antibodies.
Parabilis Medicines' successful IPO, raising $745 million, underscores the strong investor interest in its innovative Helicon platform designed to target traditionally "undruggable" proteins. This app...
Parabilis CEO Mathai Mammen on biotech's record IPO
endpts.com·Jun 10, 2026
Parabilis Medicines achieved the largest biotech IPO in history, raising $670 million on the Nasdaq, which will be used to fund cancer drug development, according to CEO Mathai Mammen.
Parabilis Medicines has set a new record for the largest biotech IPO in history, raising $670 million. This significant capital influx is earmarked for funding their cancer drug development. For someo...
STAT+: Your sepsis algorithm shouldn’t require a time machine
statnews.com·Jun 10, 2026
The article discusses the challenges faced by sepsis algorithms in healthcare, emphasizing that these algorithms should not require overly complex or unrealistic data inputs, akin to needing a "time machine." It highlights issues with quirky healthcare data that complicate accurate predictions and the need for better AI integration in medical prognosis.
The content is not accessible due to a subscription requirement, and there is no actionable insight provided in the available text that directly pertains to healthtech, biotech, digital health, or rel...
Novartis and Orionis strike second molecular glue deal for $40M upfront
endpts.com·Jun 10, 2026
Novartis has expanded its partnership with Orionis Biosciences by entering into a second molecular glue deal valued at $40 million upfront, with potential further payments totaling up to $1.4 billion.
Novartis' decision to deepen its collaboration with Orionis Biosciences, marked by a $40 million upfront investment, signals a strong endorsement of molecular glue technology's potential in drug disco...
STAT+: Hope for Kendall Square’s lab market
statnews.com·Jun 10, 2026
The article discusses the current state of Kendall Square's lab market, highlighting the challenges faced by biotech firms such as Sanofi, which halted a Phase 3 study due to ineffectiveness, and the significant IPO of Parabilis Medicines, raising $670 million. It also addresses the ongoing debate in Europe over drug pricing amid rising healthcare costs and pressures from pharmaceutical companies.
For a professional tracking biotech and healthtech trends, the most actionable insight from the content is the significant capital raised by Parabilis Medicines in their $670 million IPO. This marks t...
Shattuck raises $75M; Servier inks neuro ASO pact with n-Lorem Foundation
endpts.com·Jun 10, 2026
Shattuck Labs has raised $75 million through a public offering, selling over 10.5 million shares at $4 each. Additionally, Servier has entered into a partnership with the n-Lorem Foundation focused on neuro ASO development.
Shattuck Labs' recent $75 million public offering indicates significant investor interest in their biotech innovations, which could be a signal for potential investment opportunities in companies focu...
Biotech pay analysis: 12 execs with $35M+ M&A golden parachutes
endpts.com·Jun 10, 2026
An analysis by Endpoints News reveals that twelve biotech executives collectively received nearly $1 billion in exit packages from mergers and acquisitions, each exceeding $35 million.
This content primarily focuses on the financial windfalls for biotech executives from M&A activities, detailing significant exit packages. If you're tracking investment signals in biotech, the key tak...
<a href="https://www.fiercebiotech.com/biotech/ada-more-cagrisema-weight-loss-data-coming-jury-still-out-amid-tough-retatrutide" hreflang="en">ADA: Novo’s Lange says ‘jury still out’ on CagriSema amid tough retatrutide comparisons</a>
fiercebiotech.com·Jun 10, 2026
Novo Nordisk's CagriSema is being compared to Eli Lilly's retatrutide in the obesity treatment race, with CagriSema showing 23% weight loss in trials, while retatrutide demonstrated a higher 28% weight loss. Despite the early challenges, Novo's CSO remains optimistic about CagriSema's potential and ongoing trials to enhance its effectiveness.
The most valuable insight for a professional in healthtech and biotech is the competitive landscape between Novo Nordisk's CagriSema and Eli Lilly's retatrutide in obesity treatment. While retatrutide...
Ethyreal lands $101M to treat both Graves' and thyroid eye disease
endpts.com·Jun 10, 2026
Ethyreal Bio has secured $101 million in funding to develop treatments for Graves' disease and thyroid eye disease, both of which are related autoimmune conditions. The company is backed by Atlas Venture and Medicxi.
Ethyreal Bio has secured $101M to address the autoimmune conditions Graves’ disease and thyroid eye disease, indicating a significant investment opportunity in the niche autoimmune treatment market. T...
<a href="https://www.fiercebiotech.com/biotech/big-pharma-backed-sonothera-sounds-125m-series-b-bubble-based-genetic-delivery" hreflang="en">Big Pharma-backed SonoThera sounds off with $125M series B for bubble-based genetic delivery</a>
fiercebiotech.com·Jun 10, 2026
SonoThera, a Bay Area biotech company, has raised $125 million in a Series B funding round led by Vida Ventures, with backing from major pharmaceutical companies. The funding will advance their innovative ultrasound-mediated delivery system for genetic medicines, targeting conditions like Duchenne muscular dystrophy, and aims to address challenges associated with traditional gene therapy delivery methods.
SonoThera's $125 million Series B funding, backed by major pharma players, highlights the significant interest in their bubble-based genetic delivery system that could overcome traditional gene therap...
<a href="https://www.fiercebiotech.com/biotech/ethyreal-bio-manifests-101m-pack-biotechs-gunning-amgens-tepezza" hreflang="en">Ethyreal Bio manifests with $101M in pack of biotechs gunning for Amgen’s Tepezza</a>
fiercebiotech.com·Jun 10, 2026
Ethyreal Bio has emerged from stealth with $101 million in funding to advance its anti-TSHR antibody, ETHY-001, aimed at treating thyroid eye disease and Graves' disease, positioning itself against Amgen's Tepezza. The company plans to initiate a first-in-human trial this year, joining a competitive landscape of biotech firms targeting similar conditions.
Ethyreal Bio's emergence from stealth with $101 million in funding to advance its anti-TSHR antibody for thyroid eye disease and Graves' disease signals a significant competitive move in the biotech s...
<a href="https://www.fiercebiotech.com/biotech/novartis-sticks-2nd-deal-molecular-glue-biotech-orionis-worth-14b" hreflang="en">Novartis sticks 2nd deal with molecular glue biotech Orionis, this one worth up to $1.4B</a>
fiercebiotech.com·Jun 10, 2026
Novartis has signed a second collaboration deal with Orionis Biosciences, committing $40 million upfront and potentially up to $1.4 billion in milestone payments to develop therapeutics using Orionis' molecular glue technology. This partnership aims to target challenging therapeutic areas and follows a previous agreement established in 2020.
The most valuable insight for someone tracking biotech and healthtech is Novartis' continued investment in molecular glue technology through a significant $1.4 billion deal with Orionis Biosciences. T...
<a href="https://www.fiercebiotech.com/biotech/cancer-focused-parabilis-upsized-670m-ipo-breaks-new-record-biotechs" hreflang="en">Cancer-focused Parabilis’ upsized $670M IPO breaks new record for biotechs</a>
fiercebiotech.com·Jun 10, 2026
Parabilis Medicines has achieved a record-breaking $670 million IPO, the largest in biotech history, by offering 33.5 million shares at $20 each. The funds will primarily be used to advance its cancer treatment pipeline, including a phase 3 trial for its Wnt/β-catenin pathway inhibitor, zolucatetide.
The record-breaking $670 million IPO of Parabilis Medicines signals a renewed investor appetite for biotech IPOs, particularly for companies with innovative platforms like helicon peptides targeting p...
<a href="https://www.fiercebiotech.com/biotech/sanofi-halts-phase-3-autoimmune-trial-early-over-lackluster-efficacy" hreflang="en">Sanofi halts phase 3 autoimmune trial early over insufficient efficacy as pipeline woes continue</a>
fiercebiotech.com·Jun 10, 2026
Sanofi has prematurely halted a phase 3 clinical trial for its autoimmune therapy riliprubart due to insufficient efficacy, marking another setback for the company amidst ongoing pipeline challenges. This decision follows a series of recent clinical failures and could potentially benefit competitors in the immunoglobulin market.
Sanofi's decision to halt its phase 3 trial for the autoimmune drug riliprubart due to insufficient efficacy underscores the critical importance of robust mid-phase data for pipeline viability in drug...
Parabilis' $670M IPO sets new biotech record, will fund cancer drug
endpts.com·Jun 10, 2026
Parabilis has set a new record in the biotech industry with a $670 million IPO, which will be used to fund the development of a cancer drug, despite the competitive landscape dominated by large AI IPOs.
Parabilis' recent $670M IPO, setting a new biotech record, highlights significant investor confidence in funding cancer drug development despite the current focus on AI IPOs. This underscores the ongo...
<a href="https://www.fiercehealthcare.com/payers/pcma-unveils-new-policy-platform-aimed-drug-affordability" hreflang="en">PCMA unveils new policy platform aimed at drug affordability</a>
fiercehealthcare.com·Jun 9, 2026
The Pharmaceutical Care Management Association (PCMA) has introduced a new policy platform aimed at reducing drug costs, proposing six strategies that focus on increasing competition among drug manufacturers and enhancing transparency within the pharmaceutical supply chain. Key recommendations include limiting anti-competitive practices, shortening the exclusivity period for biologics, and promoting the use of electronic tools to inform patients about lower-cost medication options.
The PCMA's new policy platform proposes actionable reforms such as reducing the monopoly period for biologic therapies to encourage biosimilar adoption and increasing pricing transparency from drug wh...
<a href="https://www.fiercebiotech.com/cro/executive-assistant-chief-executive-charles-river-ceo-birgit-girshick-next-big-transition-cro" hreflang="en">From executive assistant to chief executive: Charles River CEO Birgit Girshick on ‘the next big transition’ in the CRO industry</a>
fiercebiotech.com·Jun 9, 2026
Birgit Girshick, CEO of Charles River Laboratories, emphasizes the importance of technology and increased collaboration in the contract research organization (CRO) industry to enhance data sharing and improve drug development outcomes. As she leads the company through a transition period following recent challenges, Girshick aims to maintain employee morale and align CRL’s mission with client goals to foster better health outcomes.
Charles River Laboratories is enhancing client collaboration through a new data-sharing platform that allows real-time access to study data. This initiative not only speeds up insight generation but a...
Gilead and Merck’s latest trial success and flop
statnews.com·Jun 9, 2026
GSK has acquired Nuvalent, a biotech company focused on targeted cancer therapies, for $10.6 billion, enhancing its lung cancer portfolio ahead of FDA decisions on two of Nuvalent's drugs. The latest biotech news also includes trial results from Gilead and Merck.
GSK's acquisition of Nuvalent for $10.6 billion is a significant move, expanding its portfolio in lung cancer treatments with two FDA-reviewed drugs targeting genetic mutations. This highlights the im...
Pharma and biotech salaries: Top-paying companies of 2025
endpts.com·Jun 9, 2026
In 2025, the average salary for workers in the biopharma sector was $116,648, which is approximately 30% higher than the average salary for employees in other industries, according to an analysis by Endpoints News.
The content doesn't provide specific insights directly relevant to healthtech, biotech, or digital health sectors. However, the mention of Parabilis' $670M IPO as a new biotech record could signal a s...
Dexcom RCT suggests CGM benefits for broad diabetes population
statnews.com·Jun 9, 2026
A recent trial by Dexcom suggests that continuous glucose monitoring (CGM) offers significant benefits for a wide range of diabetes patients, highlighting its potential for broader clinical integration alongside advancements in wearable technology and updates from Apple in health tech.
The most valuable insight for you from this content is that a recent randomized controlled trial (RCT) by Dexcom suggests that continuous glucose monitoring (CGM) can benefit a broader population of i...
STAT+: What’s changed since the last major Ebola outbreak
statnews.com·Jun 9, 2026
The article discusses recent health news, highlighting a controversial federal alcohol report that suggests even low drinking levels may increase disease risk, which faced suppression due to claims of bias from lawmakers and industry groups. Additionally, it touches on developments in wearable health data and other health-related topics.
The content mentions an "inevitable development" for wearables data, which could be a crucial signal for those in healthtech and digital health. This suggests that advancements or changes in how weara...
Parabilis Medicines has increased its IPO plans to potentially raise up to $637 million, aiming to surpass the record set by Kailera Therapeutics. The funds will primarily support the development of its lead drug, zolucatetide, for treating desmoid tumors and other rare cancers.
Parabilis Medicines is making headlines by potentially setting a new record for biotech IPOs with a target of up to $637 million, indicating strong market confidence in their novel helicon peptides pl...
<a href="https://www.fiercebiotech.com/biotech/lilly-licenses-alzecure-alzheimers-asset-1b-biobucks" hreflang="en">Lilly moves deeper into Alzheimer’s research with AlzeCure licensing deal</a>
fiercebiotech.com·Jun 9, 2026
Eli Lilly has entered a licensing agreement with AlzeCure Pharma for a gamma-secretase modulator treatment for Alzheimer's disease, potentially worth up to $1 billion. The treatment aims to reduce harmful amyloid-beta protein production and may also serve as a preventive measure against Alzheimer's development.
Eli Lilly's recent licensing deal with AlzeCure Pharma highlights a significant opportunity in the Alzheimer's therapeutic landscape, with the potential to tap into a market projected to increase eigh...
<a href="https://www.fiercebiotech.com/biotech/ada-astrazenecas-oral-glp-1-shows-competitive-efficacy-standard-tolerability-phase-2" hreflang="en">ADA: AZ’s oral GLP-1 shows ‘competitive efficacy’ in phase 2, setting stage for pivotal program</a>
fiercebiotech.com·Jun 9, 2026
AstraZeneca's oral GLP-1 receptor agonist, elecoglipron, has shown promising results in phase 2 trials for weight loss and glycemic control in patients with obesity and Type 2 diabetes, surpassing expectations and positioning the company for significant future revenue in obesity treatments. The company plans to advance elecoglipron into phase 3 studies and explore its use in combination therapies.
AstraZeneca's oral GLP-1 receptor agonist, elecoglipron, has demonstrated competitive efficacy in phase 2 trials for obesity and Type 2 diabetes, with promising weight loss and glycemic control result...
STAT+: Wearables, and the flood of data they generate, inch closer to entering the clinic
statnews.com·Jun 9, 2026
Wearable device companies Oura and Whoop are enabling users to connect virtually with clinicians through their apps, potentially integrating consumer health data into clinical care. However, experts caution that the use of such data in medical decision-making remains limited and requires further validation.
The recent move by wearable device companies Oura and Whoop to enable virtual clinician connections directly through their apps marks a significant step towards integrating consumer health data into c...
<a href="https://www.fiercebiotech.com/medtech/galmed-acquires-colospan-45m-deal-it-eyes-6b-gi-dx-market" hreflang="en">Galmed acquires Colospan in $4.5M deal as it eyes $6B GI dx market</a>
fiercebiotech.com·Jun 9, 2026
Galmed Pharmaceuticals has acquired Colospan for $4.5 million to establish a gastrointestinal diagnostics platform targeting a $6 billion market, gaining access to Colospan's device technology and clinical programs. Meanwhile, CeQur raised $100 million to support the commercialization of its insulin patch, and ResMed completed a $340 million acquisition of Noctrix Health to enhance its sleep tech portfolio with a device for treating restless legs syndrome.
Galmed Pharmaceuticals' acquisition of Colospan for $4.5 million is a strategic move to enter the $6 billion gastrointestinal diagnostics market with a focus on developing their GI platform. Notably, ...
<a href="https://www.fiercebiotech.com/medtech/roche-will-continue-eu600m-diagnostics-investment-germany-warns-future-risk" hreflang="en">Roche sticks with €600M diagnostics investment in Germany but warns of future risk</a>
fiercebiotech.com·Jun 9, 2026
Roche has confirmed its €600 million investment in a diagnostic production site in Penzberg, Germany, despite other companies like Eli Lilly and Boehringer Ingelheim cutting their investments due to new government healthcare policies. However, Roche expressed concerns about future investments in Germany due to the uncertainty introduced by these policy changes.
Roche's continued €600 million investment in their diagnostic production site in Germany, despite other companies like Eli Lilly and Boehringer cutting back due to new regulatory pressures, signals co...
Build your own newsroom
Add your own sources, define your topics, and get personalized digests delivered to your inbox.